LOGIN  |  REGISTER
Amneal Pharmaceuticals
Viking Therapeutics

Community Health Systems Completes Divestiture of Mooresville, North Carolina Hospital to Duke Health

April 01, 2025 | Last Trade: US$2.40 0.05 -2.04

FRANKLIN, Tenn. / Apr 01, 2025 / Business Wire / Community Health Systems, Inc. (NYSE: CYH) announced today that subsidiaries of the Company completed the divestiture of Lake Norman Regional Medical Center in Mooresville, North Carolina, and related businesses, to subsidiaries of Duke University Health System, Inc. for $284 million. The entry into the definitive agreement for this transaction was announced on December 11, 2024, and the closing was effective April 1, 2025.

About Community Health Systems, Inc.

Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company’s affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 36 distinct markets across 14 states. The Company’s subsidiaries own or lease 72 affiliated hospitals with more than 10,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. More information about the Company can be found on its website at www.chs.net.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page